Infusion-Based Treatment for Early Alzheimer's Disease
Lecanemab (Leqembi): A Patient’s Guide to Getting the Infusion
What happens if your doctor thinks you may be a candidate for lecanemab?
If you or a family member has recently been diagnosed with mild cognitive impairment or early Alzheimer's disease, you may have heard about lecanemab (Leqembi®).
Lecanemab is one of the first treatments designed to target an underlying feature of Alzheimer's disease rather than simply treating its symptoms.
However, not everyone with memory problems or Alzheimer's disease is a candidate.
There is a fairly detailed process involved in determining whether treatment is appropriate and safe. This guide walks through that process step by step.
What is lecanemab?
Lecanemab is an anti-amyloid medication. It is designed to bind to and help remove beta-amyloid protein that has accumulated in the brain.
The FDA has approved lecanemab for Alzheimer's disease, but treatment is intended to be started in people who are in the mild cognitive impairment or mild dementia stage of the disease—the stages in which patients were studied in the major clinical trials.
This is an important distinction.
Lecanemab is not intended for people with moderate or severe Alzheimer's dementia, and having a positive amyloid test by itself does not mean that treatment is appropriate.
The ideal candidate generally has:
- A diagnosis of mild cognitive impairment due to Alzheimer's disease, or mild Alzheimer's dementia
- Evidence that Alzheimer's disease is the likely cause of the cognitive problems
- Positive evidence of amyloid in the brain
- Cognitive testing consistent with an early stage of Alzheimer's disease
- An MRI that does not show findings that make treatment too risky
- No major medical contraindication to treatment
- The ability, with family or caregiver support when needed, to participate in the ongoing infusion and MRI schedule
Step 1: Determine how severe the memory problem is
One of the most important parts of the evaluation is determining how advanced the cognitive impairment is.
Your doctor will generally use several pieces of information rather than relying on a single test.
These may include:
- Your history
- A family member's observations
- Neurological examination
- Cognitive testing
- Assessment of your ability to function independently
- Brain imaging
- Laboratory testing
- Alzheimer's disease biomarkers
The goal is to determine whether you are in the early stage of Alzheimer's disease, when lecanemab is appropriate.
What is the MoCA?
You may have heard your doctor mention a MoCA, or Montreal Cognitive Assessment.
The MoCA is a brief cognitive screening test scored from 0 to 30 points.
It examines several areas of thinking, including:
- Short-term memory
- Attention
- Concentration
- Executive functioning
- Language
- Visuospatial skills
- Orientation
- Delayed recall
A higher score generally indicates better performance.
However, the MoCA is not an Alzheimer's disease test.
A person can have a relatively good MoCA score and still have Alzheimer's disease, particularly early in the disease. Conversely, a low MoCA score does not automatically mean that Alzheimer's disease is the cause of the cognitive problems.
Education, language, hearing, vision, anxiety, depression, fatigue, and other medical conditions can all affect performance.
Is there a specific MoCA score required to receive lecanemab?
This is an important question, and the answer is more complicated than simply saying "you need a MoCA of X."
The FDA prescribing information does not specify a particular MoCA score that every patient must achieve.
The original lecanemab clinical trial used an MMSE score greater than 22 and less than 30 at screening and baseline. The Alzheimer's Association Appropriate Use Recommendations translate this into an MMSE of approximately 22–30 or another cognitive screening score compatible with early Alzheimer's disease.
The MoCA can be used as one of those alternative cognitive screening measures, but there is no universally accepted FDA-mandated MoCA cutoff.
This is important because different medical centers and insurance companies may use somewhat different thresholds.
For example, some institutional or insurance policies have used:
- MoCA ≥17
- MoCA ≥18
- MoCA ≥19
as part of their eligibility criteria.
Some treatment programs have used MoCA ≥16 as a practical threshold.
These numbers should not be interpreted as universal FDA requirements.
Why isn't there one exact MoCA cutoff?
The reason is that cognitive screening tests are not interchangeable.
A MoCA score of 18 does not necessarily represent exactly the same level of impairment as an MMSE score of 22.
The MoCA is also more sensitive to subtle executive-function and attention problems than the MMSE.
Therefore, your doctor should consider your entire clinical picture, rather than deciding whether you qualify based on one number.
For example:
A MoCA of 17 does not automatically mean that you cannot receive lecanemab.
Likewise:
A MoCA of 24 does not automatically mean that you qualify.
Your diagnosis, functional abilities, Alzheimer's biomarkers, MRI findings, overall health, and other factors are all important.
What does my MoCA score mean?
The MoCA is scored out of 30.
As a general guide:
| MoCA score | General interpretation |
|---|---|
| 26–30 | Often considered within the normal range |
| 18–25 | Frequently seen in people with mild cognitive impairment |
| 17 or below | Increasing likelihood of more significant cognitive impairment |
These ranges are general clinical guidelines, not lecanemab eligibility rules.
There is substantial overlap between individuals.
A person's education, language, cultural background, sensory limitations, and other factors can influence the score.
This is why a specialist should interpret the score in context.
What if my MoCA is below the cutoff my doctor's clinic uses?
Don't assume that this automatically means you cannot receive treatment.
Your doctor may:
- Review the test for factors that could have affected your performance.
- Look at previous cognitive testing.
- Perform another cognitive assessment.
- Use the MMSE or another cognitive test.
- Evaluate your actual day-to-day functioning.
- Consider whether the diagnosis is MCI, mild dementia, or a more advanced stage.
- Discuss the case with a dementia specialist.
In real-world clinical practice, MoCA scores should not be interpreted in isolation. Studies of patients receiving lecanemab have specifically noted that clinicians should consider MoCA together with other clinical information rather than using the score as an independent yes/no treatment decision.
Step 2: Confirm that Alzheimer's disease is actually causing the problem
Before receiving lecanemab, your doctor needs evidence that amyloid is present in your brain.
This is critical.
Memory loss can occur for many different reasons, including:
- Alzheimer's disease
- Vascular cognitive impairment
- Lewy body disease
- Frontotemporal dementia
- Parkinson's disease
- Depression
- Medication effects
- Sleep disorders
- Thyroid disease
- Vitamin deficiencies
- Other neurological conditions
Lecanemab targets amyloid.
Therefore, the treatment generally should not be started simply because someone has memory loss.
How is amyloid confirmed?
Amyloid can generally be confirmed through:
Amyloid PET scan
A radioactive tracer is injected into a vein and a PET scan is performed.
The scan looks for amyloid plaques in the brain.
Cerebrospinal fluid testing
A lumbar puncture can be performed to obtain a small amount of cerebrospinal fluid.
The fluid can then be tested for Alzheimer's disease biomarkers.
Both approaches can provide evidence that Alzheimer's-related amyloid pathology is present. The current FDA labeling requires confirmation of amyloid beta pathology before starting lecanemab.
Step 3: Have a brain MRI
Before treatment begins, you will need a recent MRI of the brain.
The MRI is particularly important because lecanemab can cause a complication called amyloid-related imaging abnormalities, or ARIA.
Your doctor will look for things such as:
- Previous brain hemorrhages
- Microhemorrhages
- Superficial siderosis
- Significant vascular disease
- Other abnormalities that could increase treatment risk
Patients with certain MRI findings may not be appropriate candidates.
Step 4: APOE genetic testing
Your doctor may recommend testing for APOE ε4.
APOE is a gene involved in cholesterol and lipid metabolism. One version, APOE ε4, is also associated with Alzheimer's disease.
More importantly for lecanemab, people who carry two copies of APOE ε4 have a higher risk of ARIA, including symptomatic and serious ARIA. The current FDA labeling recommends APOE ε4 testing before treatment so that this risk can be discussed with the patient.
Having APOE ε4 does not necessarily mean that you cannot receive lecanemab.
Instead, it helps your doctor and you understand the risk involved.
Your healthcare provider should discuss the implications of genetic testing before the test is performed.
Step 5: Review your medications
Your doctor will carefully review all of your medications.
This is especially important if you take medications that affect bleeding.
Tell your doctor if you take:
- Aspirin
- Clopidogrel
- Warfarin
- Apixaban (Eliquis)
- Rivaroxaban (Xarelto)
- Dabigatran (Pradaxa)
- Other anticoagulants
- Other antiplatelet medications
Do not stop any medication on your own.
Your physician must determine whether the benefits and risks of lecanemab are appropriate in your individual situation.
Step 6: Make sure you can commit to the treatment schedule
Lecanemab requires a significant time commitment.
For the initial treatment period, IV lecanemab is administered:
Every two weeks.
Each infusion takes approximately one hour to administer.
However, the total appointment is longer because you may need monitoring before and after the infusion.
You will also need periodic MRI scans.
This means treatment can involve many medical appointments during the first year.
For patients and families, transportation can become a major practical consideration.
Before beginning treatment, ask:
- Where will my infusions occur?
- How long will each visit take?
- Who will drive me?
- Will someone need to accompany me?
- Where will my MRI scans be performed?
- How quickly can I be seen if I develop symptoms?
- Who do I call after hours?
What happens on infusion day?
1. Check-in
You will arrive at the infusion center and be checked in by the nursing staff.
Your vital signs and general condition may be assessed.
2. IV placement
A nurse will place an IV into your arm.
3. Lecanemab infusion
The medication is administered through the IV over approximately one hour.
The standard IV dose is weight-based.
The current FDA labeling specifies 10 mg/kg every two weeks during the initial treatment period.
4. Monitoring
You will be monitored during the infusion.
The staff will watch for signs of an infusion reaction.
5. Observation afterward
You may need to remain at the infusion center after the medication has finished.
This is particularly important during the first several treatments because infusion reactions are more common early in treatment.
What are infusion reactions?
Some patients experience an infusion reaction.
Possible symptoms include:
- Fever
- Chills
- Headache
- Nausea
- Vomiting
- Rash
- Changes in blood pressure
- Feeling generally unwell
Tell the nurse immediately if you develop symptoms.
The infusion can be slowed or stopped and medications can be given if necessary.
What is ARIA?
ARIA stands for amyloid-related imaging abnormalities.
It is one of the most important potential complications of anti-amyloid treatment.
There are two major types:
ARIA-E
This involves swelling or fluid-related changes in the brain.
ARIA-H
This involves small areas of bleeding or blood-product deposition.
Many cases are discovered on MRI before the patient has symptoms.
However, ARIA can sometimes cause symptoms.
These may include:
- Headache
- Confusion
- Dizziness
- Nausea
- Difficulty walking
- Visual changes
- Seizures
- Other neurological symptoms
Some cases can be serious or life-threatening.
When will I need MRI scans?
MRI monitoring is a major part of safe lecanemab treatment.
The current FDA prescribing information calls for:
- A baseline MRI before treatment
- MRI approximately one week before the 3rd infusion
- MRI approximately one week before the 5th infusion
- MRI approximately one week before the 7th infusion
- MRI approximately one week before the 14th infusion
Additional MRIs may be necessary if symptoms develop or if a previous MRI shows ARIA.
This monitoring is particularly important during the first several months of treatment, when ARIA risk is highest.
How long will I receive lecanemab?
The initial IV schedule is every two weeks.
Under the current FDA labeling, after approximately 18 months, patients may continue treatment every two weeks or transition to a maintenance regimen.
The current maintenance options include:
- IV lecanemab every four weeks, or
- A weekly subcutaneous formulation
The specific option should be discussed with your treating physician.
This is a change from the original lecanemab materials, which focused almost exclusively on the every-two-week IV regimen.
What if I have moderate Alzheimer's disease?
This is an important limitation.
Lecanemab was studied primarily in people with early Alzheimer's disease.
If someone has progressed to moderate or severe dementia, the evidence supporting treatment is not the same, and lecanemab is not intended to be initiated at those stages.
This is why cognitive testing and assessment of everyday functioning are so important.
The goal is to identify appropriate patients early enough in the disease process.
The evaluation is more than a MoCA score
It is tempting to think of lecanemab eligibility as:
"My MoCA is high enough, so I qualify."
That is not how the process works.
A better way to think about it is:
Diagnosis + stage + cognitive testing + functional status + amyloid confirmation + MRI + medical history + risk assessment = treatment decision
Your MoCA is one piece of the puzzle.
For example, two patients could both have a MoCA score of 20, but one could have Alzheimer's disease with positive amyloid testing and mild functional impairment, while the other could have vascular cognitive impairment or Lewy body disease.
They would not necessarily be candidates for the same treatment.
A typical pathway to lecanemab treatment
For many patients, the process looks something like this:
Visit 1
Memory evaluation
Your doctor reviews:
- Memory symptoms
- Medical history
- Medications
- Family history
- Daily functioning
- Cognitive testing
↓
Visit 2
Diagnostic testing
This may include:
- MRI
- Blood tests
- Amyloid PET or spinal fluid testing
↓
Visit 3
Treatment eligibility discussion
Your doctor reviews:
- Cognitive stage
- MoCA/MMSE or other cognitive testing
- Functional status
- Amyloid results
- MRI
- APOE status
- Bleeding risk
- Other medical conditions
↓
Treatment begins
IV infusion every two weeks
↓
Ongoing monitoring
Infusions + MRI scans + medical visits + monitoring for symptoms
Questions to ask your doctor
Before starting treatment, consider asking:
About diagnosis
- Do I definitely have Alzheimer's disease?
- What evidence confirms that Alzheimer's disease is causing my symptoms?
- Is amyloid present on my PET scan or spinal fluid testing?
About cognitive testing
- What was my MoCA score?
- What was my MMSE score, if performed?
- Am I still in the mild cognitive impairment or mild dementia stage?
- How does my cognitive testing compare with the patients studied in the lecanemab clinical trials?
About safety
- Does my MRI show microhemorrhages or other findings that increase my risk?
- Should I have APOE genetic testing?
- What is my individual risk of ARIA?
- Do any of my medications increase my bleeding risk?
About treatment
- Where will I receive my infusions?
- How long will each visit take?
- How often will I need MRIs?
- Who should I call if I develop a headache, confusion, dizziness, or other neurological symptoms?
- What happens if I develop ARIA?
- What happens if I miss an infusion?
About long-term treatment
- How long do you expect me to remain on treatment?
- How will we determine whether treatment is helping?
- What happens when I reach 18 months of treatment?
- Would I eventually be a candidate for maintenance dosing or the subcutaneous form?
The Bottom Line
Lecanemab is an important treatment option for some people with early Alzheimer's disease, but it is not appropriate for everyone with memory loss.
A MoCA score is an important part of the evaluation, but there is no single FDA-required MoCA cutoff.
The original clinical trial used an MMSE of greater than 22 and less than 30, while the Alzheimer's Association recommendations describe an MMSE of 22–30 or another cognitive screening score consistent with early Alzheimer's disease.
Individual health systems and insurance companies may impose their own MoCA thresholds, commonly somewhere in the 16–19 range, but these should not be confused with a universal FDA requirement.
Ultimately, the decision depends on much more than a score.
The ideal candidate has early Alzheimer's disease, confirmed amyloid pathology, appropriate cognitive and functional status, acceptable MRI findings, and a medical profile that allows treatment to be given safely.
For patients who are candidates, treatment requires a commitment to regular infusions, MRI monitoring, and ongoing communication with the treatment team.
The goal is not simply to find patients who have Alzheimer's disease. The goal is to identify patients with early Alzheimer's disease who are likely to have a reasonable balance between potential benefit and treatment risk.
This article is intended for general patient education and does not replace an individualized evaluation by a physician or other qualified healthcare professional. Lecanemab eligibility and treatment decisions should be based on the current FDA prescribing information, clinical judgment, and the patient's individual circumstances.